Shaperon secures 우리카지노 바카라사이트 for mass production process of key pipeline material for atopic dermatitis and Alzheimer's disease

[by Ji, Yong Jun] Shaperon announced on August 7 that it has successfully registered a 우리카지노 바카라사이트 for its mass production process of key raw materials used in its major pipelines, including treatments for atopic dermatitis, Alzheimer's disease, and COVID-19.

According to the company, the 우리카지노 바카라사이트ed raw material mass production process represents a technological innovation that dramatically improves efficiency and product quality compared to conventional production methods. Key improvements include simplified synthesis steps, high-purity purification, and effective impurity removal. The 우리카지노 바카라사이트 has already been granted in Japan and India, and applications have been filed in major global markets such as the United States, Europe, and China. Leveraging this intellectual property, Shaperon is formulating a strategy to ensure the long-term, stable commercialization of its pipeline and to facilitate market entry in various countries.

우리카지노 바카라사이트's proprietary raw material functions by fundamentally regulating the abnormal activation of inflammasomes, a key driver of inflammatory responses. This material is currently utilized in atopic dermatitis treatment (NuGel), COVID-19 and systemic inflammation treatment (NuSepin), and Alzheimer's disease treatment (NuCerin). Notably, the compound possesses the ability to simultaneously suppress both the initial and activation stages of inflammasome activity.

Shaperon emphasized that the scope of this patent extends beyond the protection of the novel drug substance alone. By securing intellectual property rights over the entire commercial mass production process, the company is implementing its ‘Evergreen patent strategy,’ which aims to serve as a barrier to the entry of generic competitors.

The Evergreen 우리카지노 바카라사이트 Strategy broadly expands the scope of global rights by securing 우리카지노 바카라사이트s not only for the new drug substance itself but also for each stage of the production process, including synthesis, purification, and impurity control. This effectively extends the 우리카지노 바카라사이트 life of a new drug by several decades, serving as a powerful mechanism to deter generic drug market entry over the long term. By implementing such a strategy, companies can establish a sustained revenue stream through prolonged market exclusivity in the global market, premium pricing, large-scale sales, and continued income from technology transfers and milestone payments.

Shaperon is actively leveraging its domestic and international 우리카지노 바카라사이트s for mass production technology to maximize its competitive advantage in ongoing negotiations for licensing-out (L/O), as well as co-development and distribution agreements. These efforts are being pursued in parallel with clinical trials of its new drug candidates based on proprietary raw materials. This strategy has laid the solid foundation for meeting growing market demand while ensuring price competitiveness and consistent product quality.

“This patent holds special meaning as it provides tight intellectual property protection not only for the new drug candidate itself but also for the full commercialization process,” a Shaperon official said. “We intend to maximize long-term market exclusivity and future profitability through the implementation of our evergreen patent strategy.”